Computational study on gabapentin as a potential therapy for partial seizures
Authors/Creators
- 1. Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, Hamdard Nagar, New Delhi, India.
- 2. Department of Medicine, Hamdard Institute of Medical Sciences and Research, Jamia Hamdard, Hamdard Nagar, New Delhi, India-110062.
- 3. College of Business, British University of Bahrain, Bahrain.
Description
US Food and Drug Administration (USFDA) approved gabapentin as an adjuvant treatment for refractory partial seizures and several diverse disorders. The drug has a relatively safe profile and is well tolerated; however, awareness is required to monitor the patient's medication, its misuse, and how to approach better patient fate. Despite the enormous scientific hypothesis encircling the drug, there is a requisite to research further about the novelty of the drug.
The review delineates the drug profile, synthesis, pharmacology, ADME properties, and computational study of gabapentin.